587 related articles for article (PubMed ID: 25995450)
21. Structural and functional insights into the TEAD-YAP complex in the Hippo signaling pathway.
Chen L; Loh PG; Song H
Protein Cell; 2010 Dec; 1(12):1073-83. PubMed ID: 21213102
[TBL] [Abstract][Full Text] [Related]
22. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway.
Chan P; Han X; Zheng B; DeRan M; Yu J; Jarugumilli GK; Deng H; Pan D; Luo X; Wu X
Nat Chem Biol; 2016 Apr; 12(4):282-9. PubMed ID: 26900866
[TBL] [Abstract][Full Text] [Related]
23. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
24. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
25. The Hippo Signaling Pathway in the Regulation of Skeletal Muscle Mass and Function.
Watt KI; Goodman CA; Hornberger TA; Gregorevic P
Exerc Sport Sci Rev; 2018 Apr; 46(2):92-96. PubMed ID: 29346163
[TBL] [Abstract][Full Text] [Related]
26. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
[TBL] [Abstract][Full Text] [Related]
27. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
28. Truncated TEAD-binding protein of TAZ inhibits glioma survival through the induction of apoptosis and repression of epithelial-mesenchymal transition.
Zhao W; Li LW; Tian RF; Dong QF; Li PQ; Yan ZF; Yang X; Huo JL; Fei Z; Zhen HN
J Cell Biochem; 2019 Oct; 120(10):17337-17344. PubMed ID: 31209945
[TBL] [Abstract][Full Text] [Related]
29. AMOTL2 interaction with TAZ causes the inhibition of surfactant proteins expression in lung cells.
Lucci V; Di Palma T; D'Ambrosio C; Scaloni A; Zannini M
Gene; 2013 Oct; 529(2):300-6. PubMed ID: 23911299
[TBL] [Abstract][Full Text] [Related]
30. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
31. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
[TBL] [Abstract][Full Text] [Related]
32. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
33. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
[TBL] [Abstract][Full Text] [Related]
34. Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis.
Li YW; Shen H; Frangou C; Yang N; Guo J; Xu B; Bshara W; Shepherd L; Zhu Q; Wang J; Hu Q; Liu S; Morrison CD; Sun P; Zhang J
Cell Cycle; 2015; 14(1):146-56. PubMed ID: 25602524
[TBL] [Abstract][Full Text] [Related]
35. Hippo-Yap/Taz signaling: Complex network interactions and impact in epithelial cell behavior.
van Soldt BJ; Cardoso WV
Wiley Interdiscip Rev Dev Biol; 2020 May; 9(3):e371. PubMed ID: 31828974
[TBL] [Abstract][Full Text] [Related]
36. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
[TBL] [Abstract][Full Text] [Related]
37. A cell-based screening for TAZ activators identifies ethacridine, a widely used antiseptic and abortifacient, as a compound that promotes dephosphorylation of TAZ and inhibits adipogenesis in C3H10T1/2 cells.
Kawano S; Maruyama J; Nagashima S; Inami K; Qiu W; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Nishina H; Hata Y
J Biochem; 2015 Nov; 158(5):413-23. PubMed ID: 25979969
[TBL] [Abstract][Full Text] [Related]
38. The Hippo-YAP pathway: new connections between regulation of organ size and cancer.
Zhao B; Lei QY; Guan KL
Curr Opin Cell Biol; 2008 Dec; 20(6):638-46. PubMed ID: 18955139
[TBL] [Abstract][Full Text] [Related]
39. Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.
Cao X; Zhao B
Methods Mol Biol; 2019; 1893():137-152. PubMed ID: 30565132
[TBL] [Abstract][Full Text] [Related]
40. Yap and Taz regulate retinal pigment epithelial cell fate.
Miesfeld JB; Gestri G; Clark BS; Flinn MA; Poole RJ; Bader JR; Besharse JC; Wilson SW; Link BA
Development; 2015 Sep; 142(17):3021-32. PubMed ID: 26209646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
